Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Bottles of Johnson's baby shampoo are on display in a store in New York on Tuesday April 18, 2006. (SHAHRZAD ELGHANAYAN/AP)
Bottles of Johnson's baby shampoo are on display in a store in New York on Tuesday April 18, 2006. (SHAHRZAD ELGHANAYAN/AP)

J&J profit beats forecasts as drug sales rebound Add to ...

Johnson & Johnson reported better than expected quarterly results On Tuesday, as its pharmaceutical sales rebounded with the help of newer products, including treatments for prostate cancer and hepatitis C.

The company earned $3-billion (U.S.), or $1.05 per share, in the third quarter. That compared with $3.2-billion, or $1.15 per share, in the year-earlier period.

Excluding special items, the diversified health care company earned $1.25 per share. Analysts, on average, had expected $1.21 per share, according to Thomson Reuters I/B/E/S.

Company revenue rose 6.5 per cent to $17.1-billion, topping Wall Street expectations of $16.98-billion.

In the know

Most popular videos »

Highlights

More from The Globe and Mail

Most popular